SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

AUPH RSS Feed
Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 11/17/2017 8:20:00 PM - Followers: 146 - Board type: Free - Posts Today: 0

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.
http://www.auriniapharma.com/
 

Pipeline

 

Pipeline

Pipeline

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.

 

SureTrader
Interactive Brokers Advertisement
AUPH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#5944  Sticky Note Aurinia is no longer just an LN focused Lunacy aka John Galt 11/02/17 03:34:15 PM
#6106   Just wait a few minutes it will change Maciste 11/17/17 03:58:01 PM
#6105   We are at WE again. Jesspro 11/17/17 03:39:01 PM
#6103   Not your brother for sure. Maciste 11/17/17 03:35:17 PM
#6102   Oh brother....... biotech_researcher 11/17/17 03:34:17 PM
#6101   “It will cause YOUR stock to plunge “. Maciste 11/17/17 03:22:56 PM
#6100   Remember approximately 25% of the patients will go Lunacy aka John Galt 11/17/17 02:56:40 PM
#6099   “The LN P3 trial did not have a biotech_researcher 11/17/17 02:41:04 PM
#6097   I have a question. Will the patients Hotrodder1 11/17/17 02:16:13 PM
#6096   The trials I looked at with a DMC tiv111 11/17/17 01:25:21 PM
#6095   Hey Jess, there are examples of phase 3 Lunacy aka John Galt 11/17/17 12:53:32 PM
#6094   We actually talked this about a while back tiv111 11/17/17 12:26:25 PM
#6093   Good article Luna, thanks for sharing. I know Jesspro 11/17/17 11:34:15 AM
#6092   https://www.smarteranalyst.com/2017/11/17/analyst-neil-maruoka-buys-aurinia-phar Lunacy aka John Galt 11/17/17 09:49:23 AM
#6091   Are you Confused Jess??? biotech_researcher 11/17/17 08:01:20 AM
#6090   Case is closed, your camp lost. Jesspro 11/17/17 07:39:13 AM
#6088   Jess, your logic may be amiss. If I biotech_researcher 11/16/17 01:57:29 PM
#6086   “Are you implying you know more than what biotech_researcher 11/16/17 01:23:33 PM
#6085   You did not answer my question. It’s a Jesspro 11/16/17 01:18:25 PM
#6084   Jess, this what should keep you awake at biotech_researcher 11/16/17 12:58:20 PM
#6082   Are you implying you know more than what Jesspro 11/16/17 11:05:14 AM
#6081   https://www.fool.com/investing/2017/11/16/where-will-aurinia-pharmaceuticals-be- LivingTheDream 11/16/17 10:31:38 AM
#6080   The shorts don't know anymore than the "longs" Easymoneyman00 11/16/17 08:37:08 AM
#6079   As is usually the case, the shorts know biotech_researcher 11/16/17 08:22:20 AM
#6078   Short interest is up over 11,000,000 million shares! Easymoneyman00 11/16/17 08:14:35 AM
#6077   Lupuzor- Well, it is for Lupus SLE, which biotech_researcher 11/16/17 06:39:19 AM
#6076   What do you think of Lupuzor? Heard its dragonstock 11/16/17 02:27:57 AM
#6075   This post is 100% on point and the yankees7 11/15/17 09:45:54 PM
#6073   I believe that is 100% wrong. BR trading_cyclist 11/15/17 05:39:04 PM
#6072   I hear you, but you can't always run SvsB 11/15/17 05:34:12 PM
#6071   BR owns this site, this thanks to all trading_cyclist 11/15/17 05:24:01 PM
#6070   Wow, the BR show is still going strong trading_cyclist 11/15/17 05:21:59 PM
#6069   https://www.smarteranalyst.com/2017/11/15/bull-sees-meaningful-market-potential- Lunacy aka John Galt 11/15/17 04:11:33 PM
#6068   It used to trade under $5 every day Zeppo 11/15/17 03:36:25 PM
#6067   Under $5 and we will be deep trouble zzaatt 11/15/17 02:32:24 PM
#6066   Let's all try to remember that shareholders have Zeppo 11/15/17 01:54:38 PM
#6065   Not selling? You can only sell if you Jesspro 11/15/17 01:53:52 PM
#6064   Nope. You are not going anywhere. You have SvsB 11/15/17 01:37:25 PM
#6063   I may sell down here as Bill Gross biotech_researcher 11/15/17 01:28:11 PM
#6062   My rush is I now have mostly income biotech_researcher 11/15/17 01:25:06 PM
#6061   I would rather like to see Vidpok post Jesspro 11/15/17 01:19:40 PM
#6060   I waited just over 3 years with Ariad. SvsB 11/15/17 01:04:11 PM
#6059   Can you please tell me something that we Maciste 11/15/17 12:44:16 PM
#6058   Sv, you couldn’t have said it any better. Jesspro 11/15/17 12:34:00 PM
#6057   “We” all will have to wait 2.5 years biotech_researcher 11/15/17 12:27:12 PM
#6056   I have complete confidence that this stock will SvsB 11/15/17 11:58:53 AM
#6055   All equities are speculative regardless of sector. The SvsB 11/15/17 11:49:52 AM
#6054   Just increased my holdings by 10%. 600 SantaFe Miguel 11/15/17 11:42:17 AM
#6053   Perfect explanation.... Jesspro 11/15/17 11:41:32 AM
#6052   It’s as clear as water, the WE man. Jesspro 11/15/17 10:56:43 AM
#6051   The deal is that you saying "We" indicates moosedogger 11/15/17 10:55:45 AM
PostSubject